TTP Labtech Acquires Assets from AssayMetrics
News Jan 09, 2014
TTP Labtech has consolidated its position in the field with today’s announcement of the purchase of assets from AssayMetrics Limited, Cardiff, UK a leading company in fluorescence lifetime technology (FLT).
The acquisition enhances TTP Labtech’s new ameon™ system equipped with real-time decay curve analysis (RT-DCA), licensed from Fluorescence Innovations Inc (Minneapolis, US). The ameon represents the next generation of FLT reader technology providing a combination of speed, precision, and data quality that can be readily exploited in HTS workflows.
“The development of the ameon reader introduces an exciting new dimension to FLT technology giving researchers a step-change in sample throughput and data quality,” said Dr Greg Gillispie, President of Fluorescence Innovations.
“Reception to ameon has been very positive with early feedback from beta-partners reporting superior tolerance to compound interference compared to established methodologies,” commented Dr Wayne Bowen, Chief Scientific Officer of TTP Labtech. “Increasing access to relevant instrumentation is revealing the true potential of FLT for cost critical assays to the screening community.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE